According to the Alzheimer’s Association, in 2021, Alzheimer’s disease and other forms of dementia will cost the nation $355 billion, including $239 billion in Medicare and Medicaid payments combined. Without reliable, accessible, and cost-efficient cognitive function assessment tools to provide early diagnosis and treatments to slow, stop, or prevent Alzheimer’s, the projected cost from Alzheimer’s alone is projected to reach $1.1 trillion in 2050.
The prevention and treatment of neurological diseases, including Alzheimer’s, depends heavily on early detection, but historically, there has been a lack of proper diagnostic tools. The limitations of existing cognitive and functional assessments have led to inadequate cognitive screening in older adults. Only half of all seniors are being assessed for cognitive impairment, and only one in seven seniors are receiving regular brief cognitive assessments.
Below we detail the need to refine cognitive function assessment tools, the limitations of traditional tools, and the shift towards multimodal assessments.
There is an overwhelming need to refine cognitive function assessment tools to better support physicians in their efforts to detect cognitive and functional impairment before the clinical onset of neurological diseases. Early detection means early intervention and treatment, which ultimately leads to better health outcomes.
An immense amount of research has expanded our understanding of neurological diseases like Alzheimer’s disease and Parkinson's disease, providing a better understanding of disease signatures, yet providers are still left with tools that are outdated, narrow, and produce highly variable results.
Traditional cognitive function assessment tools have a multitude of limitations that may be contributing factors to the inadequate cognitive screening of older adults. Limitations and challenges include the following:
Within our industry, we are beginning to see a shift towards multimodal assessments. Multimodal neurocognitive assessments that require patients to use more than one modality are the future of truly assessing their abilities to complete complex ADLs.
By requiring patients to complete tasks while using multiple modalities such as visual, auditory, and spatial to track aspects like eye movement, speech, and gait, we can paint a full and detailed picture of a patient’s true neurocognitive abilities. This will allow providers to detect signs of cognitive or functional impairments early on, before the clinical onset of neurological disease symptoms.
Until now, there hasn’t been a gold standard for cost-efficient, ecologically valid, and granular data measurement.
At Altoida, we are paving the way to early diagnosis and better patient care through our innovative multimodal neurocognitive assessment. We are building the world’s first Precision Neurology platform and app-based medical device to provide a more sensitive and ecologically valid method for assessing neurocognitive function in the most accurate, effective, and cost-efficient manner possible.
By completing a series of augmented reality and motor activities designed to simulate complex ADLs on a smartphone or tablet, Altoida’s device provides granular yet robust measurements of neurocognitive function across 13 neurocognitive domains:
Our device measures and analyzes nearly 800 cognitive and functional digital biomarkers that have been proven to be clinically significant through over 20 years of rigorous scientific research. Through the collection of highly granular, multimodal data from integrated smartphone or tablet sensor streams, Altoida’s device produces comprehensive neurocognitive domain scores.
Paired with our innovative artificial intelligence, this method will pioneer fully digital predictive neurological disease diagnosis. After our recent Breakthrough Device designation by the FDA, Altoida’s technology will provide patients with a predictive score that will enable a highly accurate prediction of whether a patient aged 55 and older will or will not convert from Mild Cognitive Impairment to Alzheimer’s disease within 12 months.
To learn more about how Altoida’s Precision Neurology device is revolutionizing cognitive function assessment tools, contact us today.